MDM2 and prostate cancer: Previously we reported that in human prostate cancer cells containing functional p53, GTP constituent EGCG treatment upregulates p53 and its phosphorylation on critical serine residues and p14ARF-mediated downregulation of MDM2 in p53-dependent manner [28].